FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC

FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC  OncLiveFrontline Pembrolizumab Granted Priority Review by FDA for Lower PD-L1 Cutoff in NSCLC  Targeted OncologyFDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line ...  BioSpace (press release) (blog)Full coverage

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2x86PX0